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ANRS: Agence Nationale de Recherches sur le Sida et les hépatites virales, ARV: 
antiretroviral therapy, CI: Confidence Interval, HIV : Human Immunodeficiency Virus, 
NRTI: nucleoside analogue reverse transcriptase inhibitor, NNRTI: non-nucleoside analogue 
reverse transcriptase inhibitor, SD : Standard Deviation, sdNVP : single-dose of nevirapine, 
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APPENDIX 
The ANRS 1209 Ditrame Plus study was coordinated by Didier K. Ekouevi and François 
Dabis. Ramata Toure and François Rouet were responsible for all laboratory aspects of this 
study. This study was part of the ANRS 1201/1202 Ditrame Plus project, of which members 
are listed below. 
 
Composition of the ANRS 1201/1202 and 1209 DITRAME PLUS Study Group 
 
Principal Investigators: François Dabis, Valériane Leroy, Marguerite Timite-Konan, 
Christiane Welffens-Ekra.  
Coordination in Abidjan: Laurence Bequet, Didier K. Ekouévi, Besigin Tonwe-Gold, Ida 
Viho. Methodology, biostatistics and data management: Gérard Allou, Renaud Becquet, Katia 
Castetbon, Laurence Dequae-Merchadou, Charlotte Sakarovitch, Dominique Touchard.  
Clinical team: Clarisse Amani-Bosse, Ignace Ayekoe, Gédéon Bédikou, Nacoumba 
Coulibaly, Christine Danel, Patricia Fassinou, Apollinaire Horo, Ruffin Likikouët, Hassan 
Toure.  
Laboratory team: André Inwoley, Hervé Menan, François Rouet, Ramata Touré.  
Psycho-social team: Hortense Aka-Dago, Alphonse Sihé. 
Social sciences team: Hélène Agbo, Hermann Brou, Annabel Desgrées-du-Loû, Annick 
Tijou-Traoré, Benjamin Zanou. 
Scientific Committee: Stéphane Blanche, Jean-François Delfraissy, Philippe Lepage, Laurent 









Background: Mitochondrial toxicity was described in infants exposed to long-term antiretroviral 
regimens (ARVs) containing nucleoside analogues for the prevention of mother-to-child transmission 
of HIV (PMTCT). We measured the serum lactate levels in children born to HIV-1 infected (HIV+) 
African women receiving short-term ARV PMTCT regimens.  
Methods: A prospective study was conducted in women-child pairs from the third trimester of 
pregnancy to three months of life. The exposed group was formed by children exposed in utero to 
nucleoside analogue ARVs, zidovudine (ZDV) or ZDV + lamivudine (3TC) from 32-36 weeks of 
amenorrhea until delivery. All these women received nevirapine single-dose (NVPsd) at the beginning 
of labor. The children received ZDV during the first 7 days of life and a NVPsd at day 3. The control 
group was formed by infants born to HIV+ women who had received NVPsd only and not exposed to 
nucleoside analogue ARVs. Serum lactate levels were measured at 4, 6 and 12 weeks of life by Cobas 
Integra 400TM.  
Results: A total of 836 blood samples from 338 infants were collected (262 exposed and 76 controls). 
Median lactacidemia was 1.8 mmol/l, Interquartile Range [1.2-2.7 mmol/l]). Overall serum lactate 
levels ≥2.5 mmol/l, defining hyperlactatemia were observed in 39 of the 292 infants who had at least 
two serum lactate measurements, 13.4%, 95% confidence Interval [9.6-17.8%]. The three-month 
period prevalence of hyperlactatemia did not differ between the exposed group (13.1%) and the 
control group (14.3%) (p=0.84). All serum lactate levels returned to normal values in all subsequent 
samples No case of symptomatic hyperlactatemia was detected during the study period. 
Conclusion: Increased lactate levels were identified equally in infants whose mother received a short-
term of nucleoside analogues or NVPsd for PMTCT. Although not rare, hyperlactatemia was not 
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Introduction 
A possible mitochondrial toxicity has been hypothesized in infants exposed to long-term 
regimens of antiretrovirals (ARVs) used for the prevention of mother-to-child transmission of 
HIV (PMTCT), following a case report of symptomatic severe lactic acidosis (1). 
Subsequently, children with neurological symptoms and biochemical and histological signs of 
mitochondrial dysfunction were described within the French Perinatal Study (2, 3). In a 
systematic screening of neurological symptoms presented by uninfected children of this large 
cohort, the 18-month incidence of this phenomenon was estimated at 0.3% in children 
exposed perinatally to nucleoside analogues (3). Subsequently several cohorts reported that a 
significant number of exposed but asymptomatic children had increased lactate levels within 
the 6-week postnatal phase of the ARVs prophylaxis exposure (4-6) and sometimes persisting 
several weeks or months later. This biological abnormality was a probable consequence of an 
acute asymptomatic mitochondrial toxicity (3). In one of these studies, hyperlactatemia was 
defined by a lactate value ≥5/mmol/l and was observed in 26% of the infants (4). The serum 
lactate measurement was considered there as a surrogate marker of mitochondrial dysfunction 
and could thus be used to investigate mitochondrial toxicity in adults and infants (4, 7). 
However, the high potential of artefactual values of lactate level is well known for this 
laboratory measurement (8). Recently Noguera et al (6) confirmed these observational data 
with a control group and adequate biological internal controls, thus strengthening the 
hypothesis that zidovudine (ZDV) exposed children had a significant risk of transient 
asymptomatic hyperlactatemia. Long term consequences of this mitochondrial injury are not 
known.  
In Africa, where short-term regimens of ARVs are frequently used for PMTCT since 2000 (9, 
10), there has not yet been any study to explore this possible mitochondrial toxicity. We 
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infants presenting possible mitochondrial dysfunction. The objective of our study was to 
estimate the frequency of high lactate levels in infants born to HIV-1 infected women and 
exposed during pregnancy to short-term of ZDV or short-term of ZDV + lamivudine (3TC) 
used for PMTCT in comparison to infants exposed to nevirapine single-dose (NVPsd) only. 
We investigated also the risk factors associated to high lactate levels, including the maternal 










The ANRS 1209 study was a prospective observational cohort set up in neonates born to HIV-
1 infected women within the ANRS 1201/1202 Ditrame Plus project which evaluated the 
safety and field effectiveness in reducing mother-to-child transmission of HIV with short-term 
combinations of ZDV+NVPsd and of ZDV+3TC+NVPsd (11) followed by alternatives to 
prolonged breastfeeding in Abidjan, Côte d’Ivoire (12). 
 
Ethical permissions 
The ANRS 1201/1202 Ditrame Plus project was granted ethical permission in Côte d’Ivoire 
from the ethical committee of the National AIDS Control Programme, and in France from the 
institutional review board of the French Agence Nationale de Recherches sur le Sida (ANRS). 
As part of the Ditrame Plus project, the study presented here was included in the institutional 
review board approval. 
 
Patients 
Between May 2002 and February 2005, we enrolled consecutively in this sub-study three 
groups of infants born to HIV-1 infected pregnant women (Table 1). Cohort 1 was exposed to 
maternal short-term ZDV initiated at 36 weeks of amenorrhea. Cohort 2 was exposed to 
maternal short-term ZDV+3TC initiated at 32 weeks of amenorrhea. In these two cohorts, 
mothers received also NVPsd at the beginning of the labour and the newborns ZDV syrup 
(2mg/kg/6 hours) during their first week of life and NVPsd (2mg/kg) at Day 2. The third 
cohort was used as a control group formed between February 2004 and February 2005 of 
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the international (14) and national guidelines implemented after the end of the Ditrame Plus 
cohort. 
 
Biological Analyses  
The lactate levels were determined according to ACTG mitochondrial dysfunction Focus 
Group Guidelines (15). These guidelines specify in particular how the venous lactate 
specimens must be collected for this purpose. 
The serum lactate levels were systematically measured in children at 4, 6 and 12 weeks of life 
by Roche Cobas Integra 400TM in Treichville Hospital University, CeDReS laboratory in 
Abidjan. All measures were performed on the supernatant after deproteineization with internal 
quality control as suggested by the manufacturer (Roche Diagnostics, Mannheim, Germany). 
CeDReS also participated in an external quality control program of lactate measurements 
organized by a Necker University Hospital Laboratory (Paris, France). The quality control 
was performed in ASQUALAB “Assurance de qualité des laboratories d’analyses médicales” 
in Corentin Celton Hospital (Moulineaux, France). 
Capillary blood was collected in EDTA microtainer tubes (Becton Dickinson) in newborns at 
weeks 4 and 6 for the diagnosis of pediatric HIV infection. All samples collected at week 4 
were systematically processed for a plasma HIV-1 RNA viral load measurement using the 
bDNA assay or a real time polymerase chain reaction (PCR) with the quantitative Taqman 
technology (16). The same technique was applied to the 6-week sample if the first one tested 
was positive. Maternal CD4 count was measured using flow cytometry (FASCAN). 
 
Outcomes 
We defined hyperlactatemia as at least two consecutives measures of lactate levels higher than 
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measurements were also realized at 4-6 months in case of diagnosis of hyperlactatemia at an 
earlier age, for studying further the kinetics of the lactate levels in this subgroup. 
The available infant data included in the analysis of the determinants of hyperlactatemia were 
gender, HIV infection status, anthropometric data at birth (weight, length) and compliance to 
ZDV syrup intake for the post-exposure prophylaxis. Maternal data included the ARV 
regimen (type and term) during pregnancy, intrapartum dose intake, age, clinical stage and 
CD4 count.  
 
Statistical analysis 
The prevalence of hyperlactatemia was estimated with its 95 percent confidence interval (CI). 
The group comparisons used Student's t-test or the non parametric Mann-Whitney U test or 
one-way analysis of the variance (ANOVA) for quantitative variables and the Chi-2 test or 
Fisher’s exact test for qualitative variables.  
All factors potentially associated with hyperlactatemia were studied in univariate then 
multivariate logistic regression. All tests were two-sided and a p-value <0.05 was considered 
significant. All the analyses were performed with STATATM 8.0 (Stata Corporation, College 
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Results 
Description of the study sample  
Between May 2002 and February 2005, 836 blood samples were collected from 338 infants 
(140 in cohort 1, 122 in cohort 2 and 76 in the control group). Altogether, 23 infants were 
diagnosed as HIV-infected at 4 weeks: 6 (4.4%) in the ZDV group, 6 (4.9%) in the ZDV+3TC 
group and 11 (14.9%) in the sdNVP group. Among these infants, 159 (47%) initiated 
breastfeeding and 179 (53%) received formula feeding. Overall, three lactate measurements 
were performed in median per infant (range: 1-5) and the mean lactate level was 2.2 mmol/L, 
(standard deviation [SD] 1.4 mmol/L). No statistical difference of mean lactate level was 
observed between the three groups (p=0.242) and between the exposed and the controls 
groups (p=0.530) when adjusting on the timing of the blood samples collected (Table 2).  
 
Frequency of hyperlactatemia 
A total of 292 infants (86%) who had at least two consecutive lactate measurements were 
available for this estimation, and 39 of them had hyperlactatemia. Thus, the prevalence of 
hyperlactatemia in this population was 13.4%, (CI: 9.6-17.8%). It was 11.6% (CI: 6.3-19.0%) 
among 112 infants from cohort 1, 14.5%, (CI: 8.5-22.5%) in 110 infants of cohort 2 and 
14.3%, (CI: 7.1%-24.7%) in 70 infants of control group (p=0.79) (Figure 1). The prevalence 
of hyperlactatemia was 13.1% in the overall exposed group and 14.3% in the control group 
(p=0.84). Serious lactate levels (≥ 5 mmol/L) were identified in 34/836 (4.0%) blood samples 
collected and five children presented confirmed (≥ 2 samples) severe hyperlactatemia among 
292 infants who had two consecutive measurements. No difference was observed between the 
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Factors associated with hyperlactatemia in infants exposed to nucleoside antiretrovirals 
In univariate then multivariate analyses, none of the following variables was found to be 
significantly associated with hyperlactatemia: child characteristics (gender, HIV status at 
week 4, twin birth, infant ZDV prophylaxis, birth weight) and maternal characteristics 
(duration of prepartum prophylaxis with ZDV, CD4, WHO clinical stage and age). No 
difference of frequency of hyperlactatemia was found according to the infant HIV status at 
week-4 (4.8% in HIV-infected infant versus 14.0% among the non HIV-infected, p=0.229).  
 
Evolution of neonatal hyperlactatemia  
The kinetics of hyperlactatemia is documented in 28 of 31 infants exposed to ZDV (n=12) or 
ZDV+3TC (n=19) and shows a return to normal values for 25 children (Figure 2). Three 
infants had persistent hyperlactatemia at month 6 and their lactate levels were respectively 3.3 




None of the children who presented a biologically confirmed hyperlactatemia in the first three 
months of life developed any of the following symptomatic clinical manifestations: abdominal 
pain, muscular or neurological symptoms, either before or after the biological diagnosis was 
made. There was not record of special clinical manifestation in the three children with 
persistent hyperlactatemia. All these infants with abnormal biological values were 
subsequently clinically followed at least until their second birthday and one male infant death 
was reported at week 38, whose presumptive cause was severe anemia. His serum lactate 
values were 2.6 mmol/L at week-4, 3.3 mmol/L at week-6, 1.8 mmol/L at month 3 and 2.7 
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Discussion 
In adults and children, the rise of lactate levels may be observed in physiological 
circumstances such as during and immediately after exercise, in hypermetabolic states and in 
the context of disease conditions (8). Thus, the diagnosis of nucleoside reverse transcriptase 
inhibitors related hyperlactatemia requires exclusion of others causes, such as dehydratation, 
vigorous exercise, alcohol intoxication, renal failure, hyperthyroidism and exposure to others 
drugs (17). However, hyperlactatemia is commonly artefactual due to sampling methods: in 
vivo by the use of tourniquets or as a consequence of fist clenching or hand pumping when 
venous specimens are drawn and in vitro if adequate plasma collection tubes are not used (18, 
19). 
In order to understand the significance of elevated lactate levels in infants exposed to ARVs, 
our study included also a control group formed by infants born to HIV-infected mothers and 
exposed to sdNVP, a non nucleoside reverse transcriptase inhibitor.  
We have also undertaken internal and external quality controls with an independent laboratory 
to validate the lactate measurements. Moreover, we defined high lactate levels as two 
consecutives levels >2.5 mmol/L, thus taking into account only high and sustained lactatemia. 
We believe therefore our estimates are minimally biased regarding an artefactual measure. 
In our study, the overall frequency of high lactate levels was estimated at 13% and did not 
differ according to the type of ARV exposure. No difference was also found between groups 
when comparing the mean value of serum lactates of the exposed and control groups.  
These results are in relative contradiction with those from a controlled study in Spain, where 
half of exposed children presented hyperlactatemia (6). This discrepancy could be explained 
by a longer exposure to NRTIs in the Spanish study, both for prenatal and postnatal periods. 
In industrialized countries, prophylactic treatment are generally initiated at the beginning of 
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addition a high dose of ZDV is given intravenously during labor, while children in our study 
were exposed in utero to oral ZDV alone in median for four weeks or to ZDV+3TC in median 
for eight weeks, and the labor dose was only given orally. As expected, we observed that the 
infants from cohort 2 had higher mean lactates than infants from cohort 1 or 3. This could be 
related to either the longer period of exposure or an exposure to two analogues nucleosides 
such as ZDV and 3TC.  
It is also important to underline that our control group took into account the pregnancy effect 
as well as the maternal HIV infection status, that was not performed in the Spanish study (6). 
We can conclude therefore that, in our study the high lactate levels although not rare, were not 
related to short-term exposure to the nucleoside analogues.  
There are potential limitations to our investigation. An enrolment bias could be discussed 
because we have enrolled the control group in a more limited time period than the other 
groups. However the impact of this selection procedure on the lactate measurements should 
be limited as all the laboratory assessments were performed by the same laboratory. We were 
not able to measure arterial pH to identify lactic acidosis, as well as the lactate-pyruvate ratio 
to explore mitochondrial function, for logistical reasons. However, the strengths of this 
observational study remain the large sample size and the use of a control group which has 
taken into account both the HIV infection status of the mother and the exposure to ARV 
drugs. Indeed, with 53 infants in each group we had a 80% statistical power to detect a mean 
difference between the infants exposed to NRTIs with mean lactate levels estimated at 2.88 
mmol/L and those not exposed to NRTIs with mean lactate levels estimated at 1.61/mmol/L 
according to the results by Nogurera et al (6).  
 
Our study allows drawing some public health conclusions. It appears clearly that lactate 
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context, although one cannot rule out the occurrence of mitochondrial injury in these cohorts 
(2-3). Based on our findings as well as the literature from industrialized countries (3), there is 
no argument to justify any routine screening of hyperlactatemia in infants exposed perinatally 
to ARVs. Long-term follow-up including clinical investigations as well as more advanced 
biological investigations of HIV-infected infants exposed perinatally to ARVs for PMTCT 
could help to detect all abnormalities which could be drug-related. The creation of an 
international registry to collect short and long-term ARV toxicity in such infants could help in 
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Table 1. Antiretroviral interventions among HIV-infected mothers and infants for the prevention of mother-to-child transmission of HIV in the 
ANRS Ditrame Plus cohort in Abidjan, Côte d’Ivoire (2002-2005).  
 
Regimens   Mother  Infants 
  Prepartum 
(gestational age at the beginning) 
Intrapartum Postpartum  Postnatal 
Ditrame Plus 1.0 
(Cohort 1, exposed) 
 ZDV 300 mg 
(36 weeks) 
 
ZDV 600 mg + NVP 200 
mg 
-  ZDV syrup 2mg/kg x 4/ day for one week and 
NVP syrup 2mg/kg on day 2-3 
Ditrame Plus 1.1 
(Cohort 2, exposed) 
 ZDV 300 mg + 3TC 150 mg 
(32 weeks) 
 
ZDV 600 mg + NVP 200 
mg 
ZDV 300 mg + 3TC 150 mg 
(3 days) 
 ZDV syrup 2mg/kg x 4/ day for one week and 
NVP syrup 2mg/kg on day 2-3 
National Program 
(Cohort 3, control) 
 
 - NVP 200 mg -  NVP syrup 2mg/kg on day 2-3 
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Table 2. Lactate values (mmol/L) according to the exposure to antiretroviral prophylaxis and the timing of the blood collection. ANRS 1209 study, 
Abidjan, Côte d’Ivoire (2002-2005).  
 
Control group  Exposed group      Overall  
Cohort 3 
sdNVP 




p*  p** p*** 
Lactate values (total)              
Number of samples  836  194  642 323 319     
Min-Max  0.2-11.7  0.6-6.3  0.3-11.7 0.3-10.5 0.2-11.7     
Mean (SD) mmol/L  2.2 (1.4)  2.3 (1.1)  2.2 (1.5) 2.0 (1.1) 2.3 (1.6) 0.009  0.530 0.242 
             
Lactate values (week-4)             
Age of infants (days)  29 [28-31]  31 [29-34]  28 [28-30] 29 [28-30] 28 [28-30]   0.570  
Number of samples  299  73  226 117 109     
Min-Max  0.2-11.7  0.9-5.7  0.2-11.7 0.6-7.5 0.2-11.7     
Mean (SD) mmol/L  2.2 (1.4)  2.2 (0.9)  2.2 (1.5) 2.1 (1.1) 2.3 (1.8) 0.283  0.976 0.499 
             
Lactate values (week-6)             
Age of infants (days)  44 [42-46]  46 [44-50]  44 [42-46] 44 [42-46] 44 [42-46]     
Number of samples  264  65  199 101 98     
Min-Max  0.3-10.5  0.9-5.7  0.3-9.9 0.6-10.5 0.3-9.9     
Mean (SD) mmol/L  2.4 (1.5)  2.3 (1.2)  2.2 (1.5) 2.2 (1.5) 2.6 (1.9) 0.149  0.638 0.273 
             
Lactate values (month-3)             
Age of infants (days)  92 [90-93]  93 [92-100]  91 [90-92] 93 [92-94] 91 [90-92]     
Number of samples  264  65  170 79 91     
Min-Max  0.3-8.1  0.9-6.3  0.3-8.1 0.3-6.3 0.4-8.1     
Mean (SD) mmol/L 
 
 2.1 (1.1)  2.3 (1.1)  2.0 (1.2) 1.7 (1.1) 2.2 (1.1) 0.006  0.104 0.006 
sdNVP = single-dose of nevirapine, ZDV = zidovudine, 3TC = lamivudine  
* Comparison between the two exposed groups, **Comparison between exposed (all) and control groups, *** Comparison between the three groups 
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Figure 1. Frequency of hyperlactatemia* in infants born to HIV-infected mothers and 
exposed to antiretovirals during pregnancy. ANRS 1269 study, Abidjan, Côte d’Ivoire 
(2002-2005). 
 
sdNVP : single-dose of nevirapine 
ZDV+sdNVP : zidovudine (ZDV) from 36 weeks of gestation and single-dose of nevirapine 
ZDV+3TC+sdNVP: zidovudine (ZDV) + lamivudine (3TC) from 32 weeks of gestation and 
single-dose of nevirapine 
 
*>=2.5 mmol/L on two consecutives measurements in a series of three 
 
 
Figure 2. Kinetics of evolution of lactate measurements & in 28 infants born from HIV-
infected mothers presenting hyperlactatemia in first three months of life. ANRS 1269 
study in the Ditrame Plus cohort in Abidjan, Côte d’Ivoire (2002-2005). 
 
 
W4 = 4 weeks of life 
W8 = 6 weeks of life 
W12=12 weeks of life 
W16-W24=between 16 and 24 weeks of life 
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